PT - JOURNAL ARTICLE AU - MICHAEL MEDINGER AU - JÖRG HALTER AU - DOMINIK HEIM AU - ANDREAS BUSER AU - SABINE GERULL AU - CLAUDIA LENGERKE AU - JAKOB PASSWEG TI - Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents DP - 2016 Jul 01 TA - Cancer Genomics - Proteomics PG - 275--279 VI - 13 IP - 4 4099 - http://cgp.iiarjournals.org/content/13/4/275.short 4100 - http://cgp.iiarjournals.org/content/13/4/275.full SO - Cancer Genomics Proteomics2016 Jul 01; 13 AB - Background/Aim: Novel agents such as thalidomide, lenalidomide and bortezomib have in part anti-angiogenic properties. In this study, we examined gene expression of angiogenic molecules in patients with plasma cell myeloma (PCM). Materials and Methods: We included 93 patients with PCM treated with novel agents (immunomodulatory drugs (IMiDs), bortezomib or a combination of both). The mRNA levels of angiogenic molecules were measured using the Human Angiogenesis RT2 Profiler PCR Array. The response evaluation was performed after three cycles. Results: Regarding all 93 patients, gene expression of 15 out of 84 genes tested (pre- and post-treatment and changes in levels pre-treatment/post-treatment) were significantly different in responders compared to non-responders. Responders had a lower expression of pro-angiogenic factors and increased expression of antiangiogenic factors. Conclusion: In the IMiD-treated groups we found significant changes of expression of angiogenic genes in responders compared to non-responders, whereas in the bortezomib-based group the difference in expression of angiogenic genes was not significant.